Literature DB >> 12222995

Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Jane Alcorn1, Patrick J McNamara.   

Abstract

Dramatic developmental changes in the physiological and biochemical processes that govern drug pharmacokinetics and pharmacodynamics occur during the first year of life. These changes may have significant consequences for the way infants respond to and deal with drugs. The ontogenesis of systemic clearance mechanisms is probably the most critical determinant of a pharmacological response in the developing infant. In recent years, advances in molecular techniques and an increased availability of fetal and infant tissues have afforded enhanced insight into the ontogeny of clearance mechanisms. Information from these studies is reviewed to highlight the dynamic and complex nature of developmental changes in clearance mechanisms in infants during the first year of life. Hepatic and renal elimination mechanisms constitute the two principal clearance pathways of the developing infant. Drug metabolising enzyme activity is primarily responsible for the hepatic clearance of many drugs. In general, when compared with adult activity levels normalised to amount of hepatic microsomal protein, hepatic cytochrome P450-mediated metabolism and the phase II reactions of glucuronidation, glutathione conjugation and acetylation are deficient in the neonate, but sulfate conjugation is an efficient pathway at birth. Parturition triggers the dramatic development of drug metabolising enzymes, and each enzyme demonstrates an independent rate and pattern of maturation. Marked interindividual variability is associated with their developmental expression, making the ontogenesis of hepatic metabolism a highly variable process. By the first year of life, most enzymes have matured to adult activity levels. When compared with adult values, renal clearance mechanisms are compromised at birth. Dramatic increases in renal function occur in the ensuing postpartum period, and by 6 months of age glomerular filtration rate normalised to bodyweight has approached adult values. Maturation of renal tubular functions exhibits a more protracted time course of development, resulting in a glomerulotubular imbalance. This imbalance exists until adult renal tubule function values are approached by 1 year of age. The ontogeny of hepatic biliary and renal tubular transport processes and their impact on the elimination of drugs remain largely unknown. The summary of the current understanding of the ontogeny of individual pathways of hepatic and renal elimination presented in this review should serve as a basis for the continued accruement of age-specific information concerning the ontogeny of clearance mechanisms in infants. Such information can only help to improve the pharmacotherapeutic management of paediatric patients.

Entities:  

Mesh:

Year:  2002        PMID: 12222995     DOI: 10.2165/00003088-200241120-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  328 in total

1.  Structure and expression of the human MDR (P-glycoprotein) gene family.

Authors:  J E Chin; R Soffir; K E Noonan; K Choi; I B Roninson
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

Review 2.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

3.  Organ distribution of glutathione transferase isoenzymes in the human fetus: differences between liver and extrahepatic tissues.

Authors:  G M Pacifici; M Warholm; C Guthenberg; B Mannervik; A Rane
Journal:  Biochem Pharmacol       Date:  1986-05-01       Impact factor: 5.858

4.  Pharmacokinetics of orally administered furosemide.

Authors:  M R Kelly; R E Cutler; A W Forrey; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

5.  Development of mechanisms for drug excretion.

Authors:  J B Hook; W R Hewitt
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

6.  Enzyme induction in neonates after fetal exposure to antiepileptic drugs.

Authors:  D Rating; E Jäger-Roman; H Nau; W Kuhnz; H Helge
Journal:  Pediatr Pharmacol (New York)       Date:  1983

Review 7.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

8.  Tissue and species differences in enzymes of epoxide metabolism.

Authors:  G M Pacifici; A R Boobis; M J Brodie; M E McManus; D S Davies
Journal:  Xenobiotica       Date:  1981-02       Impact factor: 1.908

9.  Theophylline metabolism during the first month of life and development.

Authors:  M Bonati; R Latini; G Marra; B M Assael; R Parini
Journal:  Pediatr Res       Date:  1981-04       Impact factor: 3.756

10.  Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.

Authors:  D M Grant; M Blum; M Beer; U A Meyer
Journal:  Mol Pharmacol       Date:  1991-02       Impact factor: 4.436

View more
  74 in total

Review 1.  Neonatal exposure to drugs in breast milk.

Authors:  Patrick J McNamara; Maggie Abbassi
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

2.  Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.

Authors:  Yasuhiro Tsuda; Shinji Tatami; Norio Yamamura; Yusuke Tadayasu; Akiko Sarashina; Karl-Heinz Liesenfeld; Alexander Staab; Hans-Günter Schäfer; Ichiro Ieiri; Shun Higuchi
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

3.  Mechanisms of lead and manganese neurotoxicity.

Authors:  April P Neal; Tomas R Guilarte
Journal:  Toxicol Res (Camb)       Date:  2013-03-01       Impact factor: 3.524

4.  A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.

Authors:  Chenguang Wang; Mariska Y M Peeters; Karel Allegaert; Heleen J Blussé van Oud-Alblas; Elke H J Krekels; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

5.  Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. Towards an increased knowledge of paediatric clinical pharmacology.

Authors:  Trevor N Johnson
Journal:  Eur J Clin Pharmacol       Date:  2005-10-26       Impact factor: 2.953

6.  1H-NMR metabolic profiling of human neonatal urine.

Authors:  S Trump; S Laudi; N Unruh; R Goelz; D Leibfritz
Journal:  MAGMA       Date:  2006-11-29       Impact factor: 2.310

7.  Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.

Authors:  Sam Salman; Susan Griffin; Kay Kose; Nolene Pitus; Josephine Winmai; Brioni Moore; Peter Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

8.  Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?

Authors:  Sven Björkman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 9.  The interplay between drugs and the kidney in premature neonates.

Authors:  Michiel F Schreuder; Ruud R G Bueters; Karel Allegaert
Journal:  Pediatr Nephrol       Date:  2013-11-12       Impact factor: 3.714

Review 10.  Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population.

Authors:  Ronald N Hines; Dana Sargent; Herman Autrup; Linda S Birnbaum; Robert L Brent; Nancy G Doerrer; Elaine A Cohen Hubal; Daland R Juberg; Christian Laurent; Robert Luebke; Klaus Olejniczak; Christopher J Portier; William Slikker
Journal:  Toxicol Sci       Date:  2009-09-21       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.